One partner,End to End

Start a partnership

Why Nova

Founded in 2003 in Sydney, Nova is an end-to-end partner connecting research and development, regulatory, manufacturing and commercialisation, so a medicine has one partner from licence to pharmacy shelf.

Four waysto work with Nova

Market access01 / 04

In-licensing

We actively seek and secure in-licensing partnerships to expand and diversify our product portfolio, bringing new products to market and strengthening our ability to meet evolving patient and market needs.

  1. RegistrationTaking your product through the TGA
  2. LaunchThrough pharmacy and grocery
  3. Life CycleSupply, quality and pharmacovigilance
Discuss a partnership
A gloved hand placing a vial in a lab
Licensing opportunities02 / 04

Out-licensing

We partner with pharmaceutical companies worldwide to out-license our complex generic products, enabling partners to expand their own portfolios and reach new markets with high-quality, cost-effective medicines. These partnerships are built on long-term, mutually beneficial collaboration.

  1. PortfolioMore than 300 TGA-registered products
  2. DossiersRegistered in Australia
  3. SupplyManufacturing and supply agreements
Discuss a partnership
A tablet under a microscope lens
Portfolio growth03 / 04

Portfolio management & acquisitions

As the pharmaceutical landscape evolves, pharmaceutical companies increasingly look to grow and protect their brands. Whether divesting mature or non-core brands or seeking an efficient route into Australasia, Nova is positioned as a trusted partner for both. We offer a proven stewardship model, leveraging our infrastructure, which boasts 20+ years of proven success.

Complementing this, we pursue selective brand and portfolio acquisitions that align with our strategic focus.

  1. ManageCommercial and regulatory care of your brands
  2. AcquireBrands and portfolios that fit our range
  3. GrowThrough our pharmacy and grocery reach
Discuss a partnership
Vials placed in a steel rack
Your brand04 / 04

Private label manufacturing

We help partners bring medicines to market under their own brand, from formulation and packaging to registration and ongoing supply.

With more than 20 years managing private labels for companies in Australasia, Nova has maintained strong, successful long-term partnerships with the largest grocery giants.

  1. DevelopFrom formulation to finished pack
  2. RegisterRegulatory work for your brand
  3. SupplyConsistent supply to your stores
Discuss a partnership
Blister foil running over a roller

Partners

On the shelves of Australia’s leadingpharmacies and supermarkets

FAQs

Find answers about Nova, our approach and the medicines we bring to market.

About
Products
Partnerships
Industry

A generic medicine is a pharmaceutical product containing the same active ingredient(s) as a brand-name medicine, often offered at a lower cost.

Before supply, generic medicines must be proven to be bioequivalent. In practice, this means they have the same dosage form, strength, route of administration, quality, performance characteristics and intended use.

The active ingredient, strength and dosage form match the originator brand. However, some inactive ingredients (such as binders or colourings) may differ.

Yes. Before a generic medicine can be supplied in Australia, the Therapeutic Goods Administration (TGA) must assess its quality, safety and effectiveness. The TGA requires all generic medicines to demonstrate that they work the same way in the body as the originator brand.

No. Generic medicines are held to the same stringent quality, manufacturing and safety standards as originator brands.

Developing a new medicine takes years of research and large clinical trials, the costs of which originator companies need to recover. Generic manufacturers do not need to repeat the original discovery, so we can bring medicines to market at more affordable prices. The difference in cost reflects a different cost structure, not a difference in quality.

The value of a medicine is only realised when patients can access it.

When a brand’s market exclusivity expires, generic entry introduces competition, which reduces prices and broadens availability. Without generic competition, a single supplier could retain control of the market, and high prices would limit who could access treatment.

In Australia, increased generic uptake sustains the Pharmaceutical Benefits Scheme (PBS), releases savings for reinvestment, and strengthens supply and choice. Every generic medicine dispensed through a community pharmacy contributes to these system-wide savings.

Start a conversation

Let’s talk aboutyour portfolio

Tell us about your product or portfolio and our business development team will be in touch.

Business development

info@novapharm.com.au

I’m interested in

Send enquiry
Enquiry sent

Thank you

Your enquiry is on its way. Our business development team will get back to you shortly.

Sorry, something went wrong. Please check the form and try again.

Close-up view of blue translucent liquid bubbles with small air droplets suspended inside, showcasing smooth curved surfaces and light reflections.